265 related articles for article (PubMed ID: 21351536)
1. [Dutasteride in the treatment of benign prostatic hyperplasia: an update].
Chen HJ; Chen YR
Zhonghua Nan Ke Xue; 2011 Jan; 17(1):63-7. PubMed ID: 21351536
[TBL] [Abstract][Full Text] [Related]
2. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
3. Dutasteride for the treatment of benign prostatic hyperplasia.
Wu C; Kapoor A
Expert Opin Pharmacother; 2013 Jul; 14(10):1399-408. PubMed ID: 23750593
[TBL] [Abstract][Full Text] [Related]
4. [The effects of dutasteride on voiding and storage symptoms in men with benign prostatic hyperplasia].
Tsukamoto T; Shirai T; Sakamoto S; Akiyama A; Takeuchi H; Yajima M; Terao T; Endo Y
Hinyokika Kiyo; 2010 Dec; 56(12):677-82. PubMed ID: 21273805
[TBL] [Abstract][Full Text] [Related]
5. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C;
Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
[TBL] [Abstract][Full Text] [Related]
7. Dutasteride for the treatment of prostate-related conditions.
Slater S; Dumas C; Bubley G
Expert Opin Drug Saf; 2012 Mar; 11(2):325-30. PubMed ID: 22316171
[TBL] [Abstract][Full Text] [Related]
8. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
Dolder CR
Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
[TBL] [Abstract][Full Text] [Related]
9. Effect of dutasteride on microvessel density in benign prostatic hyperplasia.
Sugie S; Mukai S; Tsukino H; Iwamoto H; Kobayashi T; Toda Y; Kamoto T
In Vivo; 2014; 28(3):355-9. PubMed ID: 24815838
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.
Na Y; Ye Z; Zhang S;
Clin Drug Investig; 2012 Jan; 32(1):29-39. PubMed ID: 22017520
[TBL] [Abstract][Full Text] [Related]
11. Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.
Hong SK; Min GE; Ha SB; Doo SH; Kang MY; Park HJ; Yoon CY; Jeong SJ; Byun SS; Lee SE
BJU Int; 2010 Apr; 105(7):970-4. PubMed ID: 19793378
[TBL] [Abstract][Full Text] [Related]
12. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
Schmidt LJ; Tindall DJ
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):32-8. PubMed ID: 20883781
[TBL] [Abstract][Full Text] [Related]
13. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
14. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
16. [Dutasteride (Avodart): a novel 5-alpha reductase inhibitor for treatment of benign prostate hypertrophy].
Vanden Bossche M; Sternon J
Rev Med Brux; 2005; 26(2):103-6. PubMed ID: 15945422
[TBL] [Abstract][Full Text] [Related]
17. [Medical treatment of patients with benign prostatic hyperplasia with 5-reductase inhibitors].
Spivak LG; Platonova DV; Yagudaev DD
Urologiia; 2019 Sep; (4):175-179. PubMed ID: 31535827
[TBL] [Abstract][Full Text] [Related]
18. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
Sun J; Xiang H; Yang LL; Chen JB
Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
[TBL] [Abstract][Full Text] [Related]
19. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
20. The effects of 5α-reductase inhibition on benign prostatic hyperplasia treated by photoselective vaporization prostatectomy with the 120 Watt GreenLight HPS laser system.
Strom KH; Gu X; Spaliviero M; Wong C
J Am Coll Surg; 2011 Feb; 212(2):244-50. PubMed ID: 21183365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]